HomeCompareMLLCF vs EQR

MLLCF vs EQR: Dividend Comparison 2026

MLLCF yields 40.32% · EQR yields 4.73%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 MLLCF wins by $195.5K in total portfolio value
10 years
MLLCF
MLLCF
● Live price
40.32%
Share price
$4.96
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$236.0K
Annual income
$40,141.97
Full MLLCF calculator →
EQR
EQR
● Live price
4.73%
Share price
$58.58
Annual div
$2.77
5Y div CAGR
15.8%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$40.5K
Annual income
$3,819.61
Full EQR calculator →

Portfolio growth — MLLCF vs EQR

📍 MLLCF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodMLLCFEQR
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, MLLCF + EQR cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
MLLCF pays
EQR pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

MLLCF
Annual income on $10K today (after 15% tax)
$3,427.42/yr
After 10yr DRIP, annual income (after tax)
$34,120.67/yr
EQR
Annual income on $10K today (after 15% tax)
$401.93/yr
After 10yr DRIP, annual income (after tax)
$3,246.67/yr
At 15% tax rate, MLLCF beats the other by $30,874.01/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of MLLCF + EQR for your $10,000?

MLLCF: 50%EQR: 50%
100% EQR50/50100% MLLCF
Portfolio after 10yr
$138.2K
Annual income
$21,980.78/yr
Blended yield
15.90%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on EQR right now

MLLCF
Analyst Ratings
2
Hold
Consensus: Hold
Altman Z
-1.2
Piotroski
1/9
EQR
Analyst Ratings
16
Buy
28
Hold
2
Sell
Consensus: Hold
Price Target
$70.35
+20.1% upside vs current
Range: $63.00 — $78.50
Altman Z
1.8
Piotroski
7/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

MLLCF buys
0
EQR buys
0
No recent congressional trades found for MLLCF or EQR in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricMLLCFEQR
Forward yield40.32%4.73%
Annual dividend / share$2.00$2.77
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%15.8%
Portfolio after 10y$236.0K$40.5K
Annual income after 10y$40,141.97$3,819.61
Total dividends collected$178.0K$16.9K
Payment frequencyquarterlyquarterly
SectorStockREIT
Analyst consensusHoldHold

Year-by-year: MLLCF vs EQR ($10,000, DRIP)

YearMLLCF PortfolioMLLCF Income/yrEQR PortfolioEQR Income/yrGap
1← crossover$14,732$4,032.26$11,248$547.57+$3.5KMLLCF
2$21,315$5,551.80$12,701$666.53+$8.6KMLLCF
3$30,314$7,507.11$14,405$814.59+$15.9KMLLCF
4$42,415$9,978.09$16,413$999.84+$26.0KMLLCF
5$58,431$13,047.54$18,795$1,232.92+$39.6KMLLCF
6$79,320$16,798.63$21,639$1,527.95+$57.7KMLLCF
7$106,185$21,312.20$25,057$1,903.80+$81.1KMLLCF
8$140,281$26,663.87$29,197$2,385.87+$111.1KMLLCF
9$183,022$32,921.38$34,250$3,008.70+$148.8KMLLCF
10$235,976$40,141.97$40,467$3,819.61+$195.5KMLLCF

MLLCF vs EQR: Complete Analysis 2026

MLLCFStock

Molecular Partners AG operates as a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic proteins. Its products candidates include Abicipar, a DARPin therapeutic candidate, which is in Phase III clinical trials for the treatment of neovascular wet age-related macular degeneration, as well as for diabetic macular edema; and MP0420, a multi-specific DARPin therapeutic candidate for the SARS-CoV-2 virus. The company develops MP0310, which is in Phase Ia clinical trials for immuno-oncology; MP0317, a tumor-localized immune agonist that activates immune cells in the tumor, which is in Phase I clinical trials; and MP0274 that is in Phase I clinical trials for HER2-positive cancers. It also develops MP0423 for treating COVID-19; MP0533, a CD3 T cell candidate for acute myeloid leukemia; and MP0250 for vascular endothelial growth factor, hepatocyte growth factor, and human serum albumin to increase half-life. Molecular Partners AG has agreements and collaboration with Novartis AG to develop, manufacture, and commercialize DARPin-conjugated radioligand therapies; Amgen SA; Allergan, Inc.; and discovery alliance with AbbVie Inc. in ophthalmology, as well as other third-party collaborators. The company was incorporated in 2004 and is headquartered in Schlieren, Switzerland.

Full MLLCF Calculator →

EQRREIT

Equity Residential is committed to creating communities where people thrive. The Company, a member of the S&P 500, is focused on the acquisition, development and management of residential properties located in and around dynamic cities that attract high quality long-term renters. Equity Residential owns or has investments in 305 properties consisting of 78,568 apartment units, located in Boston, New York, Washington, D.C., Seattle, San Francisco, Southern California and Denver.

Full EQR Calculator →
📬

Get this MLLCF vs EQR comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

MLLCF vs SCHDMLLCF vs JEPIMLLCF vs OMLLCF vs KOMLLCF vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.